Dihydrotestosterone has become shorthand for hair loss — the molecule patients google when their hairline starts to recede. But DHT is far more than a cosmetic inconvenience. It is a fundamental driver of male development, a mediator of androgenic physiology throughout life, and a hormone whose clinical story is considerably more nuanced than its reputation suggests.
What Is DHT?
Dihydrotestosterone (DHT) is a potent endogenous androgen synthesised from testosterone through the action of the enzyme 5α-reductase.1 There are two isoforms of this enzyme — type 1, expressed predominantly in the skin, liver, and non-genital tissue, and type 2, expressed in the prostate, genital skin, and hair follicles — and both contribute to circulating and tissue-level DHT concentrations.2 Crucially, DHT cannot be aromatised into oestrogen, as testosterone can. This means its androgenic effects are exerted directly and without the moderating influence of oestrogen conversion — a biochemical distinction with significant clinical consequences.1
DHT binds the androgen receptor with an affinity approximately five times greater than testosterone, and its receptor dissociation rate is slower, meaning it occupies the receptor for longer and drives a more sustained androgenic signal.3 It is, in physiological terms, the most potent naturally occurring androgen in the human body.
Synthesis and Distribution
The primary sites of DHT production are the prostate, skin, liver, and hair follicles — tissues with high local 5α-reductase activity.1 Approximately 6–8% of testosterone is converted to DHT in healthy adult males, and while serum DHT levels are considerably lower than testosterone (roughly 10% of total testosterone concentration), its potency at the receptor level means its biological impact is disproportionate to its circulating concentration.4 In women, DHT is produced in smaller quantities from adrenal and ovarian precursors, but plays a physiologically meaningful role nonetheless, particularly in skin and hair follicle biology.
Physiological Roles Across the Lifespan
Embryonic Development
DHT is indispensable for the formation of male external genitalia during foetal development. Deficiency of 5α-reductase type 2 results in ambiguous or female-appearing external genitalia in genetically male infants, despite normal testosterone levels — a condition that illustrates DHT's irreplaceable developmental role.5
Puberty
DHT drives virilisation at puberty: penile and scrotal development, growth of pubic, axillary, and facial hair, deepening of the voice, and the onset of androgenetic changes in scalp hair follicles. It also mediates prostatic growth during pubertal maturation.2
Adulthood
In adult males, DHT maintains secondary sexual characteristics, contributes to libido, supports spermatogenesis within the epididymis, and continues to influence sebaceous gland activity and body hair distribution.3
Skin and Hair
DHT is the principal androgen mediating follicular miniaturisation in androgenetic alopecia. Paradoxically, it simultaneously drives beard and body hair growth — the same molecule that thins scalp hair thickens facial hair, reflecting profound differences in follicular androgen sensitivity by anatomical site.6
The same molecule that drives male development from the womb is also responsible for androgenetic alopecia decades later — a reminder that biological signals are profoundly context-dependent.
DHT and Androgenetic Alopecia
Androgenetic alopecia — pattern hair loss — affects approximately 50% of men by age 50 and a significant proportion of women.7 In genetically predisposed individuals, DHT binds androgen receptors within the dermal papilla of scalp hair follicles, triggering a cascade that progressively shortens the anagen (growth) phase and miniaturises the follicle over successive hair cycles.6 Terminal hairs are gradually replaced by fine, depigmented vellus hairs, producing the characteristic patterns of recession and thinning.
The genetic susceptibility appears to involve polymorphisms in the androgen receptor gene on the X chromosome, which explains the maternal inheritance pattern observed clinically, as well as variation in local 5α-reductase activity and follicular androgen receptor density.8 This is why serum DHT levels do not reliably predict the severity of hair loss — it is tissue sensitivity, not circulating concentration alone, that determines follicular response.
5α-reductase inhibitors — finasteride (type 2 selective) and dutasteride (types 1 and 2) — reduce systemic DHT by 60–90% respectively and represent the most effective pharmacological interventions currently available for androgenetic alopecia in men.9
DHT and the Prostate: Reassessing the Risk
For decades, elevated DHT was associated in the clinical imagination with prostate disease. The relationship is more nuanced than that framing suggests. DHT is undeniably the dominant androgen in prostatic tissue, and prostatic growth is DHT-dependent — but the relationship between elevated circulating DHT and the risk of prostate cancer or benign prostatic hyperplasia (BPH) is not straightforward.10
Swerdloff et al., in their detailed review of DHT biochemistry and clinical implications, found that elevated blood DHT levels were not independently associated with increased risk of prostate cancer or BPH.4 This finding is consistent with the observation that men with 5α-reductase deficiency — who have very low DHT — do not develop BPH, yet men with normal or high DHT do not inevitably develop either condition. The picture that emerges is one of threshold dependency and individual tissue susceptibility, rather than a simple dose-response relationship between serum DHT and prostatic pathology.
DHT and Cardiovascular Health
The cardiovascular implications of DHT have been examined in the context of testosterone replacement therapy, where DHT is often elevated as a downstream consequence of treatment. Current evidence does not support an independent adverse cardiovascular effect of elevated DHT beyond the risks already associated with supraphysiological androgen exposure more broadly.4,11 Some data, in fact, suggest that DHT may have favourable effects on vascular smooth muscle tone and insulin sensitivity at physiological concentrations, though the evidence base remains limited and context-dependent.11
| DHT: Key Facts at a Glance | Detail |
|---|---|
| Synthesised from | Testosterone via 5α-reductase (type 1 and 2) |
| Androgen receptor affinity | ~5× greater than testosterone3 |
| Can be aromatised to oestrogen? | No |
| Primary production sites | Prostate, skin, liver, hair follicles |
| Key developmental role | Male external genitalia formation in utero5 |
| Hair follicle effect (scalp) | Miniaturisation → androgenetic alopecia6 |
| Hair follicle effect (beard/body) | Promotes growth6 |
| Prostate cancer risk (elevated DHT) | Not independently elevated4,10 |
| Cardiovascular risk (elevated DHT) | No independent adverse effect established4,11 |
The Bigger Picture
DHT is one of those molecules that invites oversimplification. It is tempting to cast it purely as a villain — the androgen responsible for hair loss, prostatic growth, and aggressive male physiology. The reality is considerably richer. DHT is essential to normal male development, is deeply involved in the maintenance of masculine characteristics throughout life, and its systemic clinical risk profile at physiological levels is more favourable than its reputation implies.
For patients concerned about hair loss, the key insight is this: the problem is not simply how much DHT you have, but how sensitive your follicles are to it. Treating androgenetic alopecia effectively requires understanding that distinction — and targeting therapy accordingly, whether through DHT suppression with 5α-reductase inhibitors, follicular protection, or combination approaches. That is a conversation worth having with a clinician who understands the endocrinology, not just the symptom.
References
- Swerdloff RS, Dudley RE, Page ST, Wang C, Salameh WA. Dihydrotestosterone: biochemistry, physiology, and clinical implications of elevated blood levels. Endocr Rev. 2017;38(3):220–254.
- Thigpen AE, Silver RI, Guileyardo JM, Casey ML, McConnell JD, Russell DW. Tissue distribution and ontogeny of steroid 5α-reductase isozyme expression. J Clin Invest. 1993;92(2):903–910.
- Grino PB, Griffin JE, Wilson JD. Testosterone at high concentrations interacts with the human androgen receptor similarly to dihydrotestosterone. Endocrinology. 1990;126(2):1165–1172.
- Swerdloff RS, Wang C. Dihydrotestosterone: a rationale for its use as a non-aromatizable androgen replacement therapeutic agent. Baillieres Clin Endocrinol Metab. 1998;12(3):501–506.
- Imperato-McGinley J, Guerrero L, Gautier T, Peterson RE. Steroid 5alpha-reductase deficiency in man: an inherited form of male pseudohermaphroditism. Science. 1974;186(4170):1213–1215.
- Randall VA. Androgens and hair growth. Dermatol Ther. 2008;21(5):314–328.
- Vary JC Jr. Selected disorders of skin appendages — acne, alopecia, hyperhidrosis. Med Clin North Am. 2015;99(6):1195–1211.
- Hillmer AM, Hanneken S, Ritzmann S, et al. Genetic variation in the human androgen receptor gene is the major determinant of common early-onset androgenetic alopecia. Am J Hum Genet. 2005;77(1):140–148.
- Gupta AK, Venkataraman M, Talukder M, Bamimore MA. Finasteride for hair loss: a systematic review. J Dermatolog Treat. 2022;33(4):1867–1875.
- Boyle P, Koechlin A, Bota M, et al. Endogenous and exogenous testosterone and the risk of prostate cancer and increased prostate-specific antigen (PSA) level: a meta-analysis. BJU Int. 2016;118(5):731–741.
- Oskui PM, French WJ, Herring MJ, Mayeda GS, Burstein S, Kloner RA. Testosterone and the cardiovascular system: a comprehensive review of the clinical literature. J Am Heart Assoc. 2013;2(6):e000272.